Adverse effects of therapy for ANCA-associated vasculitis.

Research output: Contribution to journalArticle

Authors

Colleges, School and Institutes

Abstract

The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.

Details

Original languageEnglish
Pages (from-to)391-401
Number of pages11
JournalBest Practice & Research: Clinical Rheumatology
Volume23
Issue number3
Publication statusPublished - 1 Jun 2009

Keywords

  • immunosuppression, toxicity, adverse events, ANCA-associated vasculitis, infection